Protection against cutaneous leishmaniasis by intranasal vaccination with lipophosphoglycan
- 30 March 2007
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 25 (14), 2716-2722
- https://doi.org/10.1016/j.vaccine.2006.05.093
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Chemotherapy of trypanosomiases and leishmaniasisTrends in Parasitology, 2005
- Advances in leishmaniasisThe Lancet, 2005
- The 3A1-La monoclonal antibody reveals key features of Leishmania (L) amazonensis metacyclic promastigotes and inhibits procyclics attachment to the sand fly midgutInternational Journal for Parasitology, 2005
- Re‐examination of the immunosuppressive mechanisms mediating non‐cure of Leishmania infection in miceImmunological Reviews, 2004
- NALT- versus PEYER'S-patch-mediated mucosal immunityNature Reviews Immunology, 2004
- Intranasal Vaccination against Cutaneous Leishmaniasis with a Particulated Leishmanial Antigen or DNA Encoding LACKInfection and Immunity, 2004
- Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasisVaccine, 2004
- Enhanced Replication ofLeishmania amazonensisAmastigotes in Gamma Interferon-Stimulated Murine Macrophages: Implications for the Pathogenesis of Cutaneous LeishmaniasisInfection and Immunity, 2004
- Mouse NK1+ T cellsCurrent Opinion in Immunology, 1995
- T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin‐12 and interferon‐γ and is inhibited by transforming growth factor‐βEuropean Journal of Immunology, 1994